TY  - JOUR
T1  - Do Histone Acetyltransferase Inhibitors Confer Neuroprotection Against
Neurodegenerative Disorders? An Overview
AU - Milano, Walter AU - Capasso, Anna 
JO  - Research Journal of Pharmacology
VL  - 12
IS  - 2-6
SP  - 16
EP  - 27
PY  - 2018
DA  - 2001/08/19
SN  - 1815-9362
DO  - rjpharm.2018.16.27
UR  - https://makhillpublications.co/view-article.php?doi=rjpharm.2018.16.27
KW  - Histone acetyltransferase inhibitors
KW  -neurodegenerative
KW  -disorders
KW  -idea
KW  -study
KW  -specific
KW  -support
AB  - Histone acetyltransferase inhibitors are able to induce neuroprotection because of their antioxidant
properties, so, their therapeutic use in limiting neurological damage is strongly supported. Histone
acetyltransferase inhibitors treatments should not only aim to alleviate specific symptoms but also, attempt to
delay/arrest disease progression and to repair the damaged structures. The acetylation and deacetylation of
histones are involved in the regulation of gene expression and the regular function of Histone
Acetyltransferases (HATs) and Deacetylases (HDACs) provide regulatory steps for gene expression and cell
cycle. Functional defects of these enzymes may lead to several diseases, including neurodegenerative
disorders. The studies reported in the present review support the view that thehistone acetyltransferase
inhibitors may be a key modulatory element in the control of neurodegenerative disorders. This idea is
supported by different anatomical, electrophysiological, pharmacological and biochemical data. Furthermore,
these studies support the idea of developing novel pharmacotherapies with histone acetyltransferase inhibitors
that selectively target specific area of CNS.
ER  -